2012
DOI: 10.1111/cyt.12021
|View full text |Cite
|
Sign up to set email alerts
|

Follow‐up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology

Abstract: Although in this category repeat FNA is expected rather than excision, we suggest evaluation of all AUS/FLUS patients in multidisciplinary meetings to decide management and recommend follow-up of all patients with this diagnosis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

12
86
1
1

Year Published

2013
2013
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 81 publications
(100 citation statements)
references
References 15 publications
12
86
1
1
Order By: Relevance
“…The literature contains quality studies for both groups with varied results. Malignancy rates that were reported by first group studies, including all undetermined patients for follow-up, are found between 15.7% and 44.1% (Horne Dincer et al, 2013;Chen et al, 2014;Ho et al, 2014;Hyeon et al, 2014;Rosario, 2014). In contrast, these rates are reported between 22.8% and 54% in the second group of studies that have only selected the patients who underwent surgery (Alexander et al, 2012;Jeong et al, 2013;Chen et al, 2014;Cuhaci et al, 2014;Ho et al, 2014;Park et al, 2014;Ryu et al, 2014).…”
Section: Discussionmentioning
confidence: 92%
“…The literature contains quality studies for both groups with varied results. Malignancy rates that were reported by first group studies, including all undetermined patients for follow-up, are found between 15.7% and 44.1% (Horne Dincer et al, 2013;Chen et al, 2014;Ho et al, 2014;Hyeon et al, 2014;Rosario, 2014). In contrast, these rates are reported between 22.8% and 54% in the second group of studies that have only selected the patients who underwent surgery (Alexander et al, 2012;Jeong et al, 2013;Chen et al, 2014;Cuhaci et al, 2014;Ho et al, 2014;Park et al, 2014;Ryu et al, 2014).…”
Section: Discussionmentioning
confidence: 92%
“…The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) has six categories, one of which is AUS or FLUS, which is a heterogeneous group that is difficult to classify as benign, follicular neoplasm, suspicious for malignancy, or malignant. [1][2][3][4][5][6] In AUS/FLUS, the risk of malignancy in resected nodules is 5 to 15%, but a variation from 6 to 48% is in record. [6][7][8][9] It has been reported that with repeated FNAB in AUS/ FLUS cases, about 56 to 68% will have a more definitive result and 15.6 to 48.6% will be interpreted as AUS/FLUS.…”
Section: Introductionmentioning
confidence: 99%
“…10 It has been recommended that if there is an indication for surgical intervention, it is not necessary to repeat the FNAB. 4 Although it has been suggested that the usage of AUS/FLUS should not exceed 7% of thyroid FNABs, 3,7,9,10 there is variation of this percentage from 3 to 29% across laboratories and from 2.5 to 28.6% among cytopathologists. 5 Ultrasound findings can facilitate reaching a diagnosis of nodules with AUS/FLUS, 11 although they may not differentiate benign from malignant nodules.…”
Section: Introductionmentioning
confidence: 99%
“…However, the published reports after the widespread use of BRSTC informed highly variable risk of malignancy ranging between 6 %-96,7% in this group (3)(4)(5)(6)(7)(8). The malignancy rate in AUS/FLUS category of our center was 45,8% and is placed centrally in previosly reported wide risk spectrum (3)(4)(5)(6)(7)(8).…”
Section: Discussionmentioning
confidence: 74%